European Pharmaceutical Review

JANUARY 10, 2023

The report offers predictive analysis of drugs entering the market or launching key indications in 2023. Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. Drug development in 2023 and beyond.

Drug Development 98

Drug Development Diabetes 98

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. In addition to these issues, further barriers to drug access remain in the UK and US.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. In addition to these issues, further barriers to drug access remain in the UK and US.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98